Urine PCA3 and TMPRSS2:ERG using cancer-specific markers to detect cancer

摘要

The limitations of serum prostate-specific antigen (PSA) as a prostate cancer (PCa) early detection biomarker are well described, and controversy surrounding its use in the screening setting was highlighted recently. Importantly, PSA is a prostate-specific biomarker rather than a PCa-specific biomarker. The explosion in the knowledge of gene expression changes and driving molecular events in PCa has motivated efforts to identify more PCa-specific biomarkers that may augment or outperform PSA in early detection.